$AEHR

ROGERS VERNON sold $847K of AEHR

ROGERS VERNON (Exec VP of Sales & Mktg.) sold 5,994 shares of AEHR TEST SYSTEMS (AEHR) at an average of $141.34 ($134.00–$143.77, $0.85M total) across 3 trades over 2026-08-14 to 2026-08-17.

Original reporting
SEC EDGAR · ROGERS VERNON
Published Aug 18, 2026, 5:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 6:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

This is a primary-source disclosure of an open-market sale totaling 5,994 shares at a weighted average price of $141.3442, leaving 186,232 shares after the transaction.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing without other company-specific catalysts.

03

What to watch

Insider sales often reflect diversification or tax planning; without additional context (e.g., earnings, guidance, or a concurrent company catalyst), traders should avoid over-weighting the signal.

Relevance 5/10Novelty 3/10Timing: today’s SEC Form 4 filing (filed 2026-08-18)

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported by Rogers Vernon (Exec VP of Sales & Mktg).

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR insider sale: Exec VP of Sales & Mktg Rogers Vernon sold $847,217 of AEHR shares via open-market transactions (Form 4).

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows a direct sale totaling $847k across three trades, with no 10b5-1 plan stated. Insider sales can be routine (tax/portfolio), so directional price impact is usually modest without accompanying company news.

Market effects

No sector-wide signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as less “scheduled,” but the sale size ($847k) is still small relative to typical institutional flows, limiting price impact.

Key entities

  • AEHR

    AEHR Test Systems, the company whose shares were sold by an executive insider.

  • Rogers Vernon

    Exec VP of Sales & Mktg who sold AEHR shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

$AEHRHigh

AEHR Stock Rallies As AI Test Orders And Wall Street Support Grow

Aehr Test Systems (NASDAQ: AEHR) stock rose 11.73% on growing AI test demand. The company secured a $22M follow-on order for AI chip testing equipment. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's unique position in AI production testing. The stock has high volatility, with a strong balance sheet but negative EBIT margins.